双价SARS-CoV-2疫苗鼻内免疫有效保护小鼠免受鼻部感染并完全抑制疾病发展
本研究开发了含Wuhan-1和Omicron BA.1刺突蛋白受体结合域(RBD)并负载纳米颗粒的双价SARS-CoV-2疫苗(双价RBD纳米颗粒)。小鼠鼻内接种cGAMP佐剂双价RBD-NPs疫苗后,上、下呼吸道产生强效持久抗体应答,广泛中和原始株及Delta、Omicron BA.1变异株;肺组织产生T细胞应答。该疫苗有效保护小鼠免受Wuhan-1和BA.1病毒鼻部感染,仍易感鼻部感染的小鼠无症状且鼻腔病毒产生被显著抑制,完全保护小鼠免于疾病发展和死亡。
要点
- 鼻内接种cGAMP佐剂双价RBD-NPs疫苗诱导小鼠上、下呼吸道强效持久抗体应答。
- 免疫小鼠抗体广泛中和原始株及Delta、Omicron BA.1变异株,肺组织产生T细胞应答。
- 该疫苗完全保护小鼠免于疾病发展和死亡,双价RBD平台有潜力开发为抗SARS-CoV-2通用疫苗。
核心结论
- 双价RBD纳米颗粒疫苗鼻内免疫完全保护小鼠免于疾病发展和死亡,该平台有潜力开发为抗SARS-CoV-2通用疫苗。
研究设计与样本
- 研究开发含Wuhan-1和Omicron BA.1刺突RBD蛋白并负载纳米颗粒的双价RBD-NPs疫苗,用体内模型评价免疫原性和保护效力。
主要发现
- 鼻内接种cGAMP佐剂双价RBD-NPs疫苗的小鼠产生强效持久抗体应答。
- stimulated抗体广泛中和上、下呼吸道中的原始株及Delta、Omicron BA.1变异株。
- 免疫小鼠肺组织产生T细胞应答。
- 鼻内免疫有效保护小鼠免受Wuhan-1和BA.1病毒引起的鼻部感染。
- 仍易感鼻部感染的免疫小鼠未出现任何症状,因鼻腔活化应答显著抑制病毒产生。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With the continuous emergence of coronavirus disease 2019 (COVID-19) waves, the scientific community has developed a vaccine that offers broad-spectrum protection at virus-targeted organs for inhibiting the transmission and protection of disease development. In the present study, a bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine containing receptor-binding domain (RBD) protein of spike from Wuhan-1 and omicron BA.1 loaded in nanoparticles, bivalent RBD NPs, was developed. The immunogenicity and protective efficacy of this vaccine candidate were evaluated using an in vivo model. Results showed that mice that received intranasal cGAMP-adjuvanted bivalent RBD-NPs vaccine elicited robust and durable antibody responses. The stimulated antibody broadly neutralized the ancestral strain and variants of concerns (delta and omicron BA.1) in the upper and lower respiratory tracts. Furthermore, the immunized mice developed T-cell response in their lung tissue. Importantly, intranasal immunization with this vaccine candidate efficiently protected mice from nasal infection caused by both Wuhan-1 and BA.1 viruses. Immunized mice that remained susceptible to nasal infection did not develop any symptoms. This is because activated responses in the nasal cavity significantly suppressed virus production. Another word is this nasal vaccine completely protected the mice from disease development and mortality. Therefore, the bivalent RBD vaccine platform has potential to be developed into an anti-SARS-CoV-2 universal vaccine.
引用
- Jearanaiwitayakul T, Sunintaboon P, Kittiayuwat A, et al. Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects mice from nasal infection and completely inhibits disease development. Vaccine. 2024. PMID: 38714446. doi:10.1016/j.vaccine.2024.04.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。